CRDFNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Cardiff Oncology, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026

$0.89−0.02 (-1.71%)

Close on Oct 19, 2026

Market cap: $60.58M
P/E (TTM): –
Dividend yield: –

Cardiff Oncology, Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31	FY 2007 2007-01-31	FY 2006 2006-01-31	FY 2005 2005-01-31
Cash & Equivalents	17	51	22	16	12	131	10	11	8.23	14	67	67	26	11	0.70	0.06	–	–	–	–
Short-Term Investments	41	40	53	89	129	0	–	–	0	24	0	–	–	–	–	–	–	–	–	–
Cash & Short-Term Investments	58	92	75	105	141	131	10	11	8.23	38	67	67	26	11	0.70	0.06	–	–	–	–
Receivables	0.18	0.77	0.29	0.77	0.54	0.32	0.20	0.17	0.08	0.10	0.10	0.06	0.08	0.17	0.10	–	–	–	–	–
Prepaid Expenses & Other	1.64	2.54	2.30	5.25	4.77	2.06	0.95	1.14	1.17	0.96	0.79	0.37	0.15	0.06	0.04	–	–	–	–	–
Total Current Assets	60	95	77	111	146	133	11	13	9.47	39	68	28	26	11	0.84	–	–	–	–	–
Property, Plant & Equipment	0.58	0.90	1.24	1.27	0.38	0.62	0.88	1.30	2.43	3.83	2.69	0.84	0.75	0.25	0.02	–	–	–	–	–
Gross Property, Plant & Equipment	5.05	5.04	4.99	4.68	3.82	3.63	3.48	3.41	4.50	5.59	3.55	1.37	1.10	0.51	0.24	–	–	–	–	–
Accumulated Depreciation	-4.47	-4.14	-3.75	-3.41	-3.44	-3.00	-2.60	-2.11	-2.07	-1.76	-0.85	-0.53	-0.35	-0.26	-0.22	–	–	–	–	–
Long-Term Investments	8.89	6.27	27	5.00	33	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Operating Lease Right-of-Use Assets	0.63	1.17	1.71	2.25	2.80	0.34	0.70	0	–	–	–	–	–	–	–	–	–	–	–	–
Other Long-Term Assets	0.55	0.07	1.28	1.39	0.24	0.40	0.16	0.10	0.39	1.17	0.37	0.34	0.34	0.36	0.17	–	–	–	–	–
Total Assets	62	97	82	116	150	135	13	14	12	44	71	29	27	12	1.04	–	–	–	–	–
Accounts Payable	8.09	4.82	1.97	1.96	1.44	1.37	0.66	0.66	0.83	1.13	1.04	0.75	0.29	0.18	0.93	–	–	–	–	–
Accrued Expenses	7.58	7.90	7.78	5.18	4.53	3.85	3.26	1.77	1.45	4.02	1.90	1.84	1.52	0.55	0.50	–	–	–	–	–
Current Portion of Long-Term Debt	–	–	–	–	–	–	–	0	1.33	2.36	5.23	1.90	0.20	–	–	–	–	–	–	–
Current Debt	–	–	–	–	–	–	–	0	1.33	2.36	5.23	1.90	0.20	–	–	–	–	–	–	–
Current Portion of Leases	0.73	0.71	0.69	0.68	0.55	0.86	0.87	0	–	–	–	–	–	–	–	–	–	–	–	–
Other Current Liabilities	–	–	–	0	0.04	0.04	0	–	–	–	–	–	–	–	–	–	–	–	–	–
Total Current Liabilities	16	13	10	7.81	6.56	6.12	4.78	2.92	3.95	7.80	8.20	4.49	2.01	0.73	1.43	–	–	–	–	–
Long-Term Debt	–	–	–	–	–	–	0	–	0	14	11	13	0.32	–	–	–	–	–	–	–
Long-Term Leases	0.10	0.81	1.46	2.04	2.57	0.01	0.86	0	–	–	–	–	–	–	–	–	–	–	–	–
Operating Lease Liabilities	0.83	1.52	2.15	2.72	3.12	0.87	1.73	2.50	–	–	–	–	–	–	–	–	–	–	–	–
Other Long-Term Liabilities	–	–	–	–	0	0.16	0.13	0.04	–	–	0	–	–	–	–	–	–	–	–	–
Total Liabilities	16	14	12	9.85	9.13	6.57	5.78	4.09	5.78	24	23	21	6.76	9.50	5.27	–	–	–	–	–
Total Debt	–	–	–	–	–	–	0	0	1.33	17	16	15	0.52	–	–	–	–	–	–	–
Preferred Stock	0	0	0	0	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	–	–	–	–	–
Common Stock	0.01	0.01	0.00	0.00	0.00	0.00	0.01	0.01	0.01	0.00	0.00	0.00	0.00	0.00	0.00	–	–	–	–	–
Additional Paid-In Capital	475	467	409	405	401	362	217	202	180	168	158	90	87	57	39	–	–	–	–	–
Retained Earnings	-430	-384	-340	-298	-260	-231	-209	-192	-173	-148	-109	-81	-67	-55	-44	–	–	–	–	–
Comprehensive Income & Other	0.05	0.03	-0.07	-0.40	-0.14	0	–	–	0	-0.01	0	–	–	–	–	–	–	–	–	–
Shareholders' Equity	45	83	70	106	140	128	7.31	10	6.51	20	49	8.35	20	2.17	-4.23	-5.00	-3.79	1.13	3.48	3.19
Total Equity	45	83	70	106	140	128	7.31	10	6.51	20	49	8.35	20	2.17	-4.23	-5.00	-3.79	1.13	3.48	3.19
Total Liabilities & Equity	62	97	82	116	150	135	13	14	12	44	71	29	27	12	1.04	–	–	–	–	–
Shares Outstanding(shares)	68	67	45	45	42	37	8.59	3.83	0.73	0.43	0.41	0.26	0.26	0.21	0.15	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -8320.1%
Net margin: -7884.1%
Return on equity, FY2025: -71.5%

Financial strength

Current ratio: 3.30
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 85.2%

Valuation

P/E ratio: –
Price to sales: 119.25
Price to book: 2.28
Dividend yield: –